Oral Treosulfan In Ewing's Sarcoma

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
28/11/2008		☐ Protocol		
Registration date 17/12/2008	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
25/01/2022	Cancer			

Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/a-trial-looking-treosulfan-treat-Ewings-sarcoma-come-back-after-treatment-OTIS

Study website

http://www.ctc.ucl.ac.uk/TrialDetails.aspx?TrialID=24

Contact information

Type(s)

Scientific

Contact name

Dr Maria Michelagnoli

Contact details

University College London 6th Floor Central 250 Euston Road London United Kingdom NW1 2PG

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

08/0230

Study information

Scientific Title

A phase II study to determine the efficacy and safety of conventional dose oral treosulfan in patients with advanced pre-treated Ewing's sarcoma

Acronym

OTIS

Study objectives

This is a non-randomised phase II study which aims to explore the efficacy and toxicity of oral treosulfan in patients with advanced, pre-treated Ewing's sarcoma. If conventional dose oral treosulfan is demonstrated to be active in patients with advanced Ewing's sarcoma, it is proposed that this study should be followed by a phase III prospective randomised controlled trial comparing oral etoposide (the traditional active palliation agent in solid tumours) with oral treosulfan.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Derby 1 (Trent) and Derby 2 Research Ethics Committees, 07/08/2009, ref: 09H0405-29

Study design

Non-randomised phase II study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Ewing's sarcoma

Interventions

Non-randomised phase II study of oral treosulfan in advanced pre-treated Ewing's sarcoma. Treosulfan 1 g/m^2 will be administered in three divided doses, daily over 7 days and repeated every 28 days, until disease progression, unacceptable toxicity or patient refusal.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Treosulfan

Primary outcome measure

Current primary outcomes measure as of 29/11/2011:

Objective response rate achieved: tumour response will be measured as defined by the RECIST guidelines.

Previous primary outcome measure:

Objective response rate achieved: tumour response will be measured as defined by the RECIST guidelines. Following analysis of data for initial 15 patients, if the measured success is less than or equal to 10% then the study will be stopped. Otherwise, the study will close once a total of 25 eligible patients have been enrolled.

Secondary outcome measures

Current secondary outcome measures as of 29/11/2011:

- 1. Event-free survival
- 2. Overall survival
- 3. Toxicity: if there is more than one toxic death, or more than two unexpected treatment related serious adverse events occurring in two separate individuals, an Independent Data Monitoring Committee meeting will take place and advice sought regarding continuing the trial
- 4. Duration of response
- 5. Time to progression/relapse

Previous secondary outcome measures:

- 1. Toxicity: if there is more than one toxic death, or more than two unexpected serious adverse events occurring in two separate individuals, the chief/co-investigators will consider stopping the trial
- 2. Duration of response
- 3. Time to progression
- 4. Correlation of deoxyribonucleic acid (DNA) cross-linking and retention with response and toxicity

Overall study start date

01/03/2009

Completion date

11/09/2012

Eligibility

Key inclusion criteria

Current inclusion criteria as of 29/11/2011:

1. Age less than 50 years, either sex

- 2. Histologically proven Ewing's sarcoma/peripheral neuroectodermal tumour
- 3. Patients with advanced, refractory disease who have failed at least one course of conventional chemotherapy and for whom no curative option exists
- 4. Measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST)
- 5. Evidence of disease progression within the preceding 8 weeks
- 6. Neutrophils greater than or equal to 1.5 x 10^9/l and platelet count greater than or equal to $100 \times 10^9/l$
- 7. Creatinine less than or equal to 1.5 x upper limit of normal (ULN)
- 8. Serum bilirubin and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to $1.5 \times ULN$
- 9. Performance status 0-2 (patients 16 years or older) or Lansky Performance Status greater than 30 (patients under 16 years). (n.b. patients with WHO performance status 3 due to spinal disease will be eligible provided they are otherwise medically well)
- 10. Patient able to comply with protocol treatment (swallow capsules) and follow up
- 11. Life expectancy of three months or greater
- 12. Written informed consent of patient or parent/legal guardian

Previous inclusion criteria:

9. World Health Organization (WHO) performance status greater than 3 (patients greater than 16 years); or Lansky Performance Status greater than 30

Participant type(s)

Patient

Age group

Other

Sex

Both

Target number of participants

25 patients in total

Total final enrolment

21

Key exclusion criteria

- 1. Newly diagnosed, or resectable Ewing's sarcoma
- 2. Pregnant/lactating women, or women of childbearing potential unless using effective contraception
- 3. Concurrent treatment with any other anti-cancer therapy, except palliative radiotherapy to non-target lesions
- 4. Concurrent treatment with other experimental drugs
- 5. Concurrent treatment with growth factors

Date of first enrolment

02/02/2010

Date of final enrolment

11/09/2012

Locations

Countries of recruitment

England

United Kingdom

Study participating centre University College London London

United Kingdom NW1 2PG

Sponsor information

Organisation

University College London (UK)

Sponsor details

c/o Joanna Galea-Lauri
Head of Clinical Trials
Joint UCLH and UCL Biomedical Research Unit
Ground Floor, Rosenheim Wing
25 Grafton Way
London
England
United Kingdom
WC1E 5DB

Sponsor type

University/education

Website

http://www.ucl.ac.uk/

ROR

https://ror.org/02jx3x895

Funder(s)

Funder type

Charity

Funder Name

Adam Dealey Foundation (UK)

Funder Name

Medac International (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2015		Yes	No
Plain English results		28/05/2015	25/01/2022	No	Yes